Jennifer E Amengual
机构: Columbia University
每年引用次数
引用次数
引用: 2,078
H-指数: 22
I10-指数 : 36
出版物: 141
The Aurora A Kinase Inhibitor, Alisertib, Has Broad Activity In Nonclinical Models Of T-Cell Lymphoma and Is Highly Synergistic With Romidepsin, But Not With Pralatrexate Or The Proteasome Inhibitor, Ixazomib
Kelly Zullo , Luigi Scotto , Jennifer E. Amengual , Owen A. O'Connor
Blood 122 ( 21) 5141 -5141
3
2013
Dual Targeting With The Selective Histone Deacetylase (HDAC) 6 Inhibitor, ACY-1215, and Bortezomib (BOR) Leads To Marked Disruption Of Protein Degradation Pathways and Apoptosis In Preclinical Models Of Lymphoma
Jennifer E. Amengual , Paul M Johannet , Xavier Jirau-Serrano , Kelly Zullo
Blood 122 ( 21) 648 -648
2013
The Investigational Aurora A Kinase Inhibitor Alisertib Exhibits Broad Activity in Preclinical Models of T-Cell Lymphoma and Is Highly Synergistic with Romidepsin
Kelly Zullo , Yige Guo , Laurence Cooke , Xavier Jirau Serrano
Blood 124 ( 21) 4493 -4493
8
2014
Sustained, Durable Responses with Alemtuzumab in Refractory Angioimmunoblastic T-Cell Lymphoma.
Jennifer E. Amengual , Bruce G. Raphael
Blood 114 ( 22) 2730 -2730
2009
Will new drugs change the standard of care for patients with mantle cell lymphoma
Donald S. Colbourn , Jennifer E. Amengual , Changchun Deng , Ahmed Sawas
Expert Review of Anticancer Therapy 16 ( 2) 199 -210
1
2016
Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies
Grzegorz Nowakowski , Annalisa Chiappella , Fangxin Hong , Randy D. Gascoyne
Blood 134 4092 -4092
3
2019
Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.
James N. Gerson , Elizabeth Handorf , Diego Villa , Alina S. Gerrie
Journal of Clinical Oncology 37 ( 6) 471 -480
25
2019
Manipulating the epigenome in germinal center lymphomas: is it getting easier and ezier?
Jennifer E. Amengual , Owen A. O'Connor
Clinical Cancer Research 20 ( 12) 3047 -3049
1
2014
Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma
Salvia Jain , Xavier Jirau-Serrano , Kelly M. Zullo , Luigi Scotto
Clinical Cancer Research 21 ( 9) 2096 -2106
51
2015
Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma
Jennifer E. Amengual , Paul Johannet , Maximilian Lombardo , Kelly Zullo
Clinical Cancer Research 21 ( 20) 4663 -4675
51
2015
Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma
Kelly M. Zullo , Yige Guo , Laurence Cooke , Xavier Jirau-Serrano
Clinical Cancer Research 21 ( 18) 4097 -4109
29
2015
Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib
Jennifer E. Amengual , Sathyen A. Prabhu , Maximilian Lombardo , Kelly Zullo
Clinical Cancer Research 23 ( 12) 3084 -3096
17
2017
Unique Therapeutic Approaches for Targeting Epigenetic Machinery in T-cell Lymphoma
Jacob Cogan , Jennifer E. Amengual
IntechOpen
2019
Regression of HIV-related diffuse large B-cell lymphoma in response to antiviral therapy alone.
Jennifer E. Amengual , Xinmin Zhang , Sherif Ibrahim , Lawrence B. Gardner
Blood 112 ( 10) 4359 -4360
11
2008
High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy.
Lorenzo Falchi , Ahmed Sawas , Changchun Deng , Jennifer E. Amengual
Journal of Hematology & Oncology 9 ( 1) 132 -132
24
2016
Sustained, durable responses with alemtuzumab in refractory angioimmunoblastic T-cell lymphoma
Jennifer E. Amengual , Bruce G. Raphael
Leukemia & Lymphoma 51 ( 7) 1347 -1350
5
2010
Murine models in mantle cell lymphoma
Kelly Zullo , Jennifer E. Amengual , Owen A. O'Connor , Luigi Scotto
Best Practice & Research Clinical Haematology 25 ( 2) 153 -163
6
2012
Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas
Jennifer K. Lue , Sathyen A. Prabhu , Yuxuan Liu , Yulissa Gonzalez
Clinical Cancer Research 25 ( 17) 5271 -5283
20
2019
Epigenetics and Lymphoma: Can We Use Epigenetics to Prime or Reset Chemoresistant Lymphoma Programs?
Jennifer K. Lue , Jennifer E. Amengual , Owen A. O’Connor
Current Oncology Reports 17 ( 9) 40
7
2015
Therapeutic Options for Aggressive T-Cell Lymphomas
Jennifer K. Lue , Anna Kress , Jennifer E. Amengual
Current Hematologic Malignancy Reports 12 ( 4) 269 -281
4
2017